SynthesisFrontiers in cardiovascular medicine2026
Association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease: a systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This systematic review and meta-analysis aimed to evaluate and quantitatively synthesize the available evidence on the association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease (CAD). Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched from inception to February 12, 2026, to identify relevant observational studies. Literature screening, data extraction, and quality assessment were independently performed by two reviewers. Meta-analyses were conducted using Stata 16.0, with odds ratios (ORs) and 95% confidence intervals (CIs) as effect measures. Subgroup and sensitivity analyses were further performed where appropriate. Results: A total of nine studies were included, with overall methodological quality ranging from moderate to high. Three SIRT1 polymorphisms, rs7069102, rs7895833, and rs4746720, were included in the quantitative synthesis. In the overall analysis, rs7069102 was not significantly associated with CAD susceptibility under any of the five genetic models; however, in the CAD subgroup, it showed a consistent risk effect across all genetic models. Rs7895833 was associated with increased CAD susceptibility only under the recessive model (OR = 1.49, 95% CI: 1.03-2.15). Rs4746720 showed significant associations under the dominant model (OR = 1.26, 95% CI: 1.02-1.55) and the heterozygote model (OR = 1.27, 95% CI: 1.01-1.58). Conclusion: Current evidence suggests that certain SIRT1 polymorphisms may be associated with CAD susceptibility, but the observed associations appear to vary by SNP locus, genetic model, and population or disease subgroup. Because the pooled estimates were derived mainly from unadjusted genotype frequencies and could not account for major cardiovascular risk factors, these findings should be interpreted cautiously. Further large, well-designed studies with appropriate adjustment for clinical confounders are needed to confirm these associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.